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cResults of a Prospective, Multicenter Trial With the Ventana Fenes-
trated System for Endovascular Repair of Juxtarenal and Pararenal
Aortic Aneurysms
William Quinones-Baldrich, MD,1 Andrew Holden,2 Renato Mortens,3
Matt Thompson,4 Alan Sawchuck,5 Mathew Eagleton, MD,6 and
Daniel Clair, MD6. 1Division of Vascular Surgery, University of California–
Los Angeles Medical Center, Los Angeles, Calif; 2Auckland City Hospital,
Auckland, New Zealand; 3Escuela de Medicina, Pontificia Universidad
CatÃlica de Chile, Santiago, Chile; 4St. George’s Institute, London, United
Kingdom; 5Methodist Hospital, Indianapolis, Ind; and 6Cleveland Clinic
Foundation, Cleveland, Ohio
Objective: This study assessed early and midterm safety and efficacy of
an off-the-shelf endovascular graft system (Ventana) in patients with para-
renal or juxtarenal aneurysms.
Methods: After Institutional Review Board approval, patients with
infrarenal aneurysms adjacent to or involving the origin of one or both
renal arteries were evaluated. Selection criteria included adequate access,
nonaneurysmal infrasuperior mesenteric artery neck length15 mm, and
renal stenosis 70%. Evaluation was done at discharge, 1, 6 months, 1
year, and annually to 5 years. Core laboratory computed tomography
evaluation was done for assessment of device integrity, patency, migra-
tion, endoleak, renal perfusion, and aneurysm morphology.
Results: Between 2010 and 2012, six centers enrolled 30 consecu-
tive patients with juxtarenal or pararenal aortic aneurysm. Patients (90%
men; mean age, 73 years) had a mean aneurysm sac diameter of 5.8 cm,
infrarenal neck length of 6 mm, and infrasuperior mesenteric artery neck
diameter of 24 mm and length of 26 mm. A Ventana graft system with
covered renal stents was implanted, preserving all visceral arteries. Com-
plications included a compressed renal stent due to repeat ballooning and
one extended renal cannulation time due to renal stenosis not seen on the
computed tomography scan. Procedure time averaged 2  1.5 hours.
Mean hospital stay was 3.8 days. No deaths occurred 30 days. One
intervention on day 26 for limb occlusion was due to device kink. Three
non-aneurysm-related deaths occurred during follow-up (mean, 8
months; range, 1-16 months). No rupture, conversion, stent fracture,
migration, type III endoleak, or sac expansion was observed. Small type
II endoleak was observed in six patients at 1 month and in three patients
at 6 months. One reintervention for renal stenosis due to initial renal
stent undersizing was done at 7 months. A type IA endoleak and renal
occlusion, secondary to procedural device damage, led to reintervention
on day 52 and dialysis at 5 months.
Conclusions: The multicenter experience of the Ventana Fenes-
trated System supports its safety and midterm effectiveness for the
endovascular repair of juxtarenal and pararenal aortic aneurysm. This
off-the-shelf, integrated system permits endovascular treatment of jux-
tarenal or pararenal aortic aneurysms; however, further expanded clinical
experience and longer-term follow-up are needed to more fully assess this
device system.
“Preloaded” Modification to the Trifurcated Technique for Hypogas-
tric Preservation During Aortoiliac Endovascular Aneurysm Repair
Without Device Alteration
Jason T. Lee, MD,1 Joshua I. Greenberg, MD,1 Mark A. Farber, MD,2 and
E. John Harris, Jr, MD1. 1Division of Vascular Surgery, Stanford University
Medical Center, Palo Alto, Calif; and 2Univeristy of North Carolina, Chapel
Hill, Chapel Hill, NC
Objective: Due to lack of commercially available iliac branched
devices, there have been descriptions of trifurcated techniques, home-
made branch devices, and the double-barrel/snorkel approach to pre-
serve hypogastric flow during endovascular aneurysm repair. We describe
a novel technique mimicking a “preloaded” catheter to provide through-
and-through wire access that eliminates the anatomic length restrictions
of the aforementioned techniques, obviates the need for arm access, and
can be performed without device modification.
Methods: A 78-year-old man with comorbid factors of prior stroke
after an emergency coronary artery bypass grafting procedure was found to
have a 5-cm abdominal aortic aneurysm with bilateral 4-cm iliac aneurysms
and desired an endovascular solution (Fig, A).
Results: After R hypogastric embolization, a Gore C3 main body (23
12  120) was deployed into the left common iliac (Fig, B). The introducer
sheath was doubly accessed, and a 4F glide catheter/wire was advanced
alongside the distal portion of the undeployed ipsilateral limb into the
left iliac aneurysm (black arrow). The contralateral gate of the C3 was
catheterized to mimic a “preloaded” catheter (Fig, C). The wire was
snared from the right and pulled out the right femoral sheath, providing
through-and-through wire stability over the aortic bifurcation. A 12F
sheath could then be easily advanced up and over and out the contralat-
eral gate of the C3 device, pointed at the hypogastric origin (Fig, D). The
through-and-through wire and 12F sheath were left in place, and a
shaped 7F sheath was advanced via a buddy wire/catheter (white arrow)
into the left hypogastric (Fig, E). This triaxial strategy allowed easy
advancement, positioning, and molding of a 10  59 iCast stent with a
a
a
5784  40 balloon spanning the contralateral gate to the distal hypogastric
anding zone (Fig, F). Once this “iliac branch device” was in place, a main
ody C3 was deployed infrarenal from the right side, and a bridging
7-mm limb from the left joined the two main bodies. Completion
ngiography confirmed no endoleak (Fig, G). and a postoperative com-
uted tomography angiography demonstrated complete exclusion.
Conclusions: The modification of placing a “preloaded” catheter
hrough the contralateral gate of the C3 repositionable main body
eployed in the common iliac effectively creates an iliac branch device.
ong-term follow-up will be necessary to confirm that this approach is
urable and effective without the need for second interventions.
hysician-Modified Endovascular Grafts: Early Report From an
nvestigator-Initiated Investigational Device Exemption Clinical
rial
enjamin W. Starnes, MD, and Billi Tatum, RN. Department of Surgery,
niversity of Washington, Seattle, Wash
Objective: This study determined whether a physician-modified endo-
ascular graft (PMEG) is a safe and effective method for treating patients
ith juxtarenal aortic aneurysms who are deemed unsuitable for open
urgical repair.
Methods: This nonrandomized, prospective, consecutively enroll-
ng investigational device exemption clinical trial was approved by the
nited States Food and Drug Administration. Data collected on patients
reated with a PMEG between the initiation of the study in April 2011
nd January 2012 were analyzed. All patients met strict inclusion and
xclusion criteria as defined by the study protocol. All patients underwent
reoperative computed tomography angiography and visceral duplex
xaminations. Participants were monitored with computed tomography,
isceral duplex imaging, and 4-view X-ray imaging at 30 days, 6 months,
year, and annually out to 5 years. The primary safety end point was
efined as the proportion of participants who experienced a major
dverse event 30 days of the procedure. The primary effectiveness end
oint was defined as the proportion of participants experiencing treat-
ent success.
Results: During the 8-month study period, 21 patients were con-
ented and 18 underwent the PMEG procedure. Eighteen patients had
0-day follow-up, eight had 6-month follow-up, and none had 1-year
ollow up. Seventy-four percent of the participants were male. Anatomic,
perative details, and length of stay are listed in the Table. There were 47
enestrations created for 34 renal arteries and 13 superior mesenteric
rteries (SMA). Renal artery fenestrations were stented whenever possi-
le (94%), and SMA fenestrations were left unstented. There were no
nanticipated adverse device events, no major adverse device events, and
nly one minor adverse device event, which was treated with a successful
eintervention. At 30 days, there were no type I or III endoleaks and only
wo type II endoleaks. Two patients died during the study period, one at
ay 23 from respiratory failure, and one at day 210 from urosepsis and
ongestive heart failure.
Conclusions: These preliminary data suggest that PMEG is a safe
Fig.nd effective procedure for managing patients with juxtarenal aortic
neurysms. PMEG has acceptable early rates of morbidity, mortality, and
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Volume 56, Number 2 Abstracts 579endoleak. This endovascular aortic strategy is particularly appealing for
those patients presenting with symptomatic or ruptured aortic aneurysms
until reliable off-the-shelf solutions become widely available.
Table. Operative details
Variable Mean (range)
Aneurysm diameter, mm 65 (55-91)
Proximal neck length, mm 4.8 (2-11)
Manufacture time, minutes 59 (31-78)
Procedure time, minutes 166 (96-378)
Fluoroscopy time, minutes 45 (19.7-164)
Total contrast, mL 65 (30-120)
Estimated blood loss, mL 200 (20-1000)
Length of stay, days 5.8 (1.3-23.7)
Endoleaks After Endovascular Repair of Ruptured Abdominal Aortic
Aneurysm: Should They Be Treated?
Nam T. Tran, Brandon Tyler Garland, Elina Quiroga, Benjamin Starnes, MD,
and Thomas Hatsukami. Department of Surgery, University of Washington,
Seattle, Wash
Objective: The management of ruptured abdominal aortic aneurysm
has undergone significant changes within the last decade, with endovascular
repair (rEVAR) now the preferred operative approach. We hypothesized that
some endoleaks after rEVAR can be managed expectantly, whereas others
require urgent intervention to due to ongoing hemorrhage.
Methods: In an Investigational Review Board-approved study, all
patients admitted with the diagnosis of rAAA from July 2007 to December
2011 were entered into a prospectively maintained database. Patients with
rEVAR and computed tomography angiography (CTA) performed within
the first 30 days of repair were included in the analysis. Images were analyzed
by attending radiologists for presence and type of endoleak as well as
aneurysm size. Relevant patient data, such as hemodynamic status, hemat-
ocrit level, transfusion requirement, hospital length of stay, and outcome,
were analyzed.
Results: Sixty-three patients (79% men) were identified who had
undergone rEVAR, and in 34, CTA was performed 30 days of the
procedure. The mean age was 74.5 years. Four type I endoleaks, one type III
endoleak, and seven type II endoleaks were identified. The overall endoleak
rate was 35.2% (12 of 34). Two of four type I endoleaks required urgent
reintervention due to hemodynamic instability. The patient with type III
endoleak was stable, but follow-up imaging demonstrated a retroperitoneal
hematoma and the sac diameter had increased in size and thus underwent
reintervention. No type II endoleaks required further intervention. At 2
years, all endoleaks except two of seven type II have resolved.
Conclusions: The rate of endoleak after rEVAR is higher than that
reported for elective endovascular repair. Type II endoleaks resolved spon-
taneously over time and should be managed conservatively. Conversely, type
I and III endoleaks can lead to continual rapid hemorrhage and should
undergo intervention. CTA should be performed on all rEVAR patients
before discharge.
Determinants of Abdominal Aortic Aneurysm Sac Enlargement After
Endovascular Aneurysm Repair with a Long-Term Follow-Up to 15
Years
Carlos E. Donayre, MD, Faidzal Othman, MD, George E. Kopchok, BS,
Ali Khoynezhad, MD, and Rodney A. White, MD. Department of Surgery/
Division Vascular Surgery, Harbor–University of California-Los Angeles
Medical Center, Torrance, Calif
Objective: Studies have documented abdominal aortic aneurysm
(AAA) enlargement in up to 41% of patients 5 years after endovascular repair
(EVAR). Noting limitations of patient selection and length of follow-up, the
current analysis was undertaken to assess AAA enlargement in an unselected
patient cohort with follow-up for up to 15 years after repair.
Methods: Between 1996 and 2011, 586 consecutive patients (mean
age, 73.9  9.0 years; 89.5% male; mean AAA diameter, 58  12 mm)
underwent EVAR. Of these, 196 (59%) were part of an investigational device
exemption (IDE) study and 137 (41%) received a commercially available
device (CAD). Centralized three-dimensional imaging computed tomogra-
phy surveillance (M2S, West Lebanon, NH) was available in 333 patients
(56%) over a median follow-up of 36 months (range, 1-180 months).
Multivariate and univariate Cox regression models were used to assess time
to AAA enlargement (5 mm vs baseline), estimating the hazard ratio (HR)
and 95% confidence intervals (CI) for AAA enlargement compared with
baseline.
t
eResults: The proportion of patients who developed AAA enlargement
t 1, 3, 5, and 8 years after repair was 4.5%, 12.5%, 21.6%, and 31.7%,
espectively (Fig). Mean time to enlargement was 42  38 months. Multi-
ariable analysis identified age (HR 1.045; 95% CI, 1.011-1.081; P  .01)
nd common iliac diameter (HR 1.047; 95% CI, 1.016-1.078; P .002) as
redictors of enlargement. At 15 years, enlargement occurred in 57 patients
17.1%), with secondary interventions required in 25 (endovascular in 22
nd open conversion in three). Only one rupture occurred in this group.
utcome in the IDE and CAD groups did not differ with respect to AAA
nlargement or the frequency of secondary interventions.
Conclusion: This single-center, unselected patient cohort with long-
erm CT follow-up documented AAA enlargement in a smaller proportion
f patients than has been reported in other series. Certain baseline patient
haracteristics can be identified that are associated with AAA enlargement,
ut the risk of enlargement did not differ in IDE vs CAD groups.
ase-Specific Endovascular Aneurysm Repair Simulation: A Pilot
omparison of Simulated Aneurysm Repair with Actual Live Cases
enita Chandra, MD,2 Robert Gowing, MD,1 Amy Peruzarro, BS,2 and
ason T. Lee, MD2. 1Vascular Surgery, McMaster University Medical
enter, Hamilton, Ontario, Canada; and 2Stanford University Medical
enter, Stanford, Calif
Objective: Patient-specific endovascular aneurysm repair (EVAR) sim-
lation has the potential to allow the operative team, particularly trainees, to
ehearse an entire case on the patient’s actual anatomy before performing the
ctual procedure. To better understand how closely outcomes of live cases
easured up to simulated ones, we analyzed the operative metrics of EVAR
imulations compared with previously performed cases.
Methods: Four completed actual EVAR cases were selected at random
o be “simulated.” Digital Imaging and Communications in Medicine data
rom preoperative computed tomography images were rendered into the
ROcedure Rehearsal Studio system, and the simulated cases were per-
ormed by a similarly experienced operative team of faculty and fellows. In
oth the actual and simulated cases, interval times to critical steps were
ecorded along with device components, repeat interventions, contrast
mounts, and fluoroscopy times.
Results: Compared with the actual live cases, the metrics simulated
ases were similar, including mean total operating room time (69 min),
uoroscopy time (22.8 min), and contrast usage (83.5 mL). Deployment of
he contralateral limb was used as a surrogate for cannulation complexity,
hich showed these times were significantly faster in the simulation group
completed at 39 vs 50.5 minutes). Total number of device components
sed was similar; however, the main body and iliac limb diameters were
requently different, with iliac limb lengths equivalent. The simulated cases
ad a higher incidence of type Ia endoleak that required additional proximal
allooning (no cuffs) compared with the actual cases.
Conclusions: Rehearsal of actual EVAR cases is feasible using current
imulation technology, with standard operative metrics replicated accurately
n the simulation group. Certain steps were easier on the simulator, indicat-
ng room for improvement in simulation technology, but overall procedural
onduct of the cases was similar to live case timelines. The potential educa-
Fig.ional benefits and increased procedural efficiency to both trainees and
xperienced EVAR users requires further investigation.
